Asia Pacific Blood Collection Tubes for Liquid Biopsy Market

The Asia Pacific blood collection tubes for liquid biopsy market was valued at US$ 28,746.23 million in 2023 and is expected to reach US$ 1,16,169.56 million by 2031; it is estimated to register a CAGR of 19.1% from 2023 to 2031.

Use of Liquid Biopsy in Cancer Monitoring Boosts Asia Pacific Blood Collection Tubes for Liquid Biopsy Market

There is a growing focus on employing liquid biopsy procedures for monitoring cancer growth, detecting genetic mutations, identifying signs of relapse, and predicting sensitivity to immunotherapy. The early detection of cancer results in better outcomes; for example, patients with early detection show higher remission and survival rates than those with late-stage or malignant cancer. However, it is impractical to perform serial radiological testing or invasive procedures for cancer surveillance to detect cancer in the early stages when symptoms are not evident. Liquid biopsy unlocks the possibility of periodic cancer screening through routine blood draws or urinalyses. It can identify highly specific and circulating markers for early cancer detection.

Liquid biopsy procedures are also employed for post-treatment monitoring of cancer patients. Cancer cells may persist in the body after treatment at levels below the resolution and detection levels of imaging studies; the condition is termed a minimal residual disease. This disease is considered a principal cause of cancer remission. Similar to that in cancer screening and early detection, the clinical application of liquid biopsy is limited by the sensitivity and specificity of current tests. However, due to this sensitivity limitation, liquid biopsy techniques can be used for detecting minimal residual disease for solid tumors than blood cancers. With the help of liquid biopsy, the healthcare professional can monitor the case of reoccurrence of cancer, which can then be treated early with the help of proper diagnosis.

Tumors that are initially susceptible to specific tyrosine kinase inhibitors, including gefitinib, erlotinib, crizotinib, and ceritinib, often mutate and develop resistance to these drugs. Liquid biopsy detects the changes in the tumor status and helps doctors modify the treatment strategies to avoid the development of resistance to any medication in the patient’s body. Thus, liquid biopsy allows the early detection of cancer and helps healthcare professionals determine the exact course of action for treatment. In addition, it helps monitor treatments and the condition of the patient after the treatment. Thus, there is an increase in focus on the use of liquid biopsy in the monitoring of cancer patients, which is likely to create a significant demand for blood collection tubes for liquid biopsy procedures during the forecast period.

Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Overview

The Asia Pacific blood collection tube for liquid biopsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The demand for blood collection tubes is increasing due to an upsurge in the number of cancer patients in the region. Moreover, government initiatives to enhance healthcare infrastructure and support research studies are expected to create significant opportunities for market growth during the forecast period. In China, significant government investments in healthcare infrastructure and emphasis on providing enhanced medical services benefit the blood collection tubes for liquid biopsy market. The increasing number of cancer cases is also contributing to the market growth, as it indicates the elevated need for sophisticated diagnostic tools such as liquid biopsies. In May 2017, Streck signed a distribution agreement with GenomePrecision Technology, an integrated molecular diagnostics distributor in China, for its cell stabilization, molecular, urinalysis, and flow cytometry products. Cell-Free DNA BCT and Cell-Free RNA BCT (both stabilize nucleated blood cells), and Cell-Free DNA Urine Preserve are among Streck's cell stabilization products. This signifies that key market players in China focus on enhancing their product access to grab growth opportunities in the market in this country. Further, biotechnology companies such as Vazyme Biotech and CNWTC offer products for cfDNA tubes, liquid biopsy kits, drug discovery, molecular research, and more.

Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Blood Collection Tubes for Liquid Biopsy Strategic Insights

Strategic insights for the Asia Pacific Blood Collection Tubes for Liquid Biopsy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Blood Collection Tubes for Liquid Biopsy Report Scope

Asia Pacific Blood Collection Tubes for Liquid Biopsy Regional Insights

The geographic scope of the Asia Pacific Blood Collection Tubes for Liquid Biopsy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Segmentation 

The Asia Pacific blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.

By product, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.

In terms of material, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.

By application, the Asia Pacific blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.

In terms of end user, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.

Based on country, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China segment held the largest share of Asia Pacific blood collection tubes for liquid biopsy market in 2023.

Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the Asia Pacific blood collection tubes for liquid biopsy market.